The Polycythemia Vera Market was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.5 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several factors, including the rising prevalence of polycythemia vera (PV), advancements in treatment options, and an increasing awareness of the disease among healthcare professionals and patients. The market...